Advertisement
Race Oncology Limited

Race Oncology Limited (RAC.AX) Stock Competitors & Peer Comparison

See (RAC.AX) competitors and their performances in Stock Market.

RAC.AXASX
HealthcareBiotechnology
$2.29
$0.01(0.44%)
Australian Market opens in 49h 2m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
RAC.AXA$2.29+4.09%447M-110.14-A$0.02N/A
CSL.AXA$121.81+2.91%56.4B12.66A$9.30+3.62%
TLX.AXA$16.88-0.82%5.8B-619.99-A$0.03N/A
MSB.AXA$2.06+0.98%2.7B-13.79-A$0.15N/A
NEU.AXA$16.74-5.16%2.2B72.37A$0.23N/A
PYC.AXA$1.54-8.33%941.6M-35.42-A$0.05N/A
OPT.AXA$0.60+0.00%820.8M6.14A$0.10N/A
CUV.AXA$10.25-1.63%517.2M15.92A$0.64+0.49%
SPL.AXA$0.74+3.52%298.9M112.70A$0.01N/A
OCC.AXA$0.76+4.86%159.9M-26.67-A$0.03N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

RAC.AX vs CSL.AX Comparison July 2026

RAC.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAC.AX stands at 447M. In comparison, CSL.AX has a market cap of 56.4B. Regarding current trading prices, RAC.AX is priced at A$2.29, while CSL.AX trades at A$121.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAC.AX currently has a P/E ratio of -110.14, whereas CSL.AX's P/E ratio is 12.66. In terms of profitability, RAC.AX's ROE is -0.47%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, RAC.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RAC.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions